Salute e Benessere
EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
Asceneuron has completed five early-stage clinical trials, showing that their treatment effectively reaches the brain and targets the OGA enzyme. Asceneuron plans to initiate its first Phase 2 clinical study later this year.
"This high caliber life sciences investor syndicate further validates the potential of our OGA inhibitor pipeline and leadership in the field of tauopathies. We are excited to be working with the LSP Dementia Fund given their outstanding track record in the field of Alzheimer's disease as we advance our lead asset ASN51 into Phase 2 clinical development, recognizing its potential to significantly expand treatment options for patients with Alzheimer's disease".
"Dementia and other neurodegenerative diseases are some of the greatest healthcare challenges of our time. With our LSP Dementia Fund, EQT Life Sciences can invest in innovative companies across the neurodegenerative spectrum. Asceneuron is exactly this kind of company. Its clinical pipeline has breakthrough potential to change patients' lives for the better and we're delighted to be joining Asceneuron on its journey."
EQT Press Office, press@eqtpartners.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-invests-in-asceneuron-a-neurodegeneration-therapeutics-company-as-part-of-usd-100-million-series-c-financing-round-302197836.html